The Mumbai-based drug major, in a statement, said it has launched Fexuprazan tablets (40 mg) in India under the brand name Fexuclue, a novel potassium-competitive acid blocker (PCAB). The product ...

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of.

Future growth depends on IP extension, new indications, and stronger market penetration amid evolving PCAB competition ... extended exclusivity for Voqeuzna tablets. Its H. pylori-indicated ...

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ...